A kinetic view of GPCR allostery and biased agonism.
暂无分享,去创建一个
Arthur Christopoulos | Patrick M Sexton | Robert G Parton | P. Sexton | A. Christopoulos | L. May | J. R. Lane | R. Parton | J. R. Lane | J Robert Lane | Lauren T May
[1] Leigh A. Stoddart,et al. Allosteric interactions across native adenosine-A3 receptor homodimers: quantification using single-cell ligand-binding kinetics , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] A. T. Nguyen,et al. Extracellular Loop 2 of the Adenosine A1 Receptor Has a Key Role in Orthosteric Ligand Affinity and Agonist Efficacy , 2016, Molecular Pharmacology.
[3] M. J. Chalmers,et al. Ligand-dependent perturbation of the conformational ensemble for the GPCR β2 adrenergic receptor revealed by HDX. , 2011, Structure.
[4] Arthur Christopoulos,et al. Signalling bias in new drug discovery: detection, quantification and therapeutic impact , 2012, Nature Reviews Drug Discovery.
[5] R. Lefkowitz,et al. Beta-adrenergic receptors: evidence for negative cooperativity. , 1975, Biochemical and biophysical research communications.
[6] B. Disse,et al. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. , 1993, Life sciences.
[7] P. Strange,et al. Co‐operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics , 2010, Journal of neurochemistry.
[8] Terry Kenakin,et al. Ligand-selective receptor conformations revisited: the promise and the problem. , 2003, Trends in pharmacological sciences.
[9] S. Charlton,et al. Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays , 2010, British journal of pharmacology.
[10] S. Charlton,et al. Long‐lasting target binding and rebinding as mechanisms to prolong in vivo drug action , 2010, British journal of pharmacology.
[11] Ralf C. Kling,et al. Functionally selective dopamine D2/D3 receptor agonists comprising an enyne moiety. , 2013, Journal of medicinal chemistry.
[12] Robert J. Lefkowitz,et al. β-Adrenergic receptors: Evidence for negative cooperativity , 1975 .
[13] P. Seeman. Targeting the dopamine D2 receptor in schizophrenia , 2006, Expert opinion on therapeutic targets.
[14] A. Christopoulos,et al. Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor. , 2014, Journal of medicinal chemistry.
[15] M. Burghammer,et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.
[16] P. Leff,et al. The two-state model of receptor activation. , 1995, Trends in pharmacological sciences.
[17] Arthur Christopoulos,et al. Novel Allosteric Modulators of G Protein-coupled Receptors* , 2015, The Journal of Biological Chemistry.
[18] A. IJzerman,et al. Agonists for the adenosine A1 receptor with tunable residence time. A Case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines. , 2014, Journal of medicinal chemistry.
[19] A. IJzerman,et al. Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time , 2012, British journal of pharmacology.
[20] N. Birdsall,et al. Modification of the binding properties of muscarinic receptors by gallamine. , 1983, Molecular pharmacology.
[21] Albert C. Pan,et al. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs , 2013, Nature.
[22] R. Stevens,et al. Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.
[23] R. Lefkowitz,et al. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.
[24] Stephen M. Husbands,et al. Structural insights into μ-opioid receptor activation , 2015, Nature.
[25] P. Gmeiner,et al. Histidine 6.55 Is a Major Determinant of Ligand-Biased Signaling in Dopamine D2L Receptor , 2011, Molecular Pharmacology.
[26] Arthur Christopoulos,et al. Emerging paradigms in GPCR allostery: implications for drug discovery , 2013, Nature Reviews Drug Discovery.
[27] J. Violin,et al. Biased ligands: pathway validation for novel GPCR therapeutics. , 2014, Current opinion in pharmacology.
[28] Sudarshan Rajagopal,et al. Quantifying Ligand Bias at Seven-Transmembrane Receptors , 2011, Molecular Pharmacology.
[29] J. Black,et al. An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation , 1985, British journal of pharmacology.
[30] Tudor I. Oprea,et al. A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.
[31] P Ghanouni,et al. Functionally Different Agonists Induce Distinct Conformations in the G Protein Coupling Domain of the β2Adrenergic Receptor* , 2001, The Journal of Biological Chemistry.
[32] Arthur Christopoulos,et al. Crystal structures of the M1 and M4 muscarinic acetylcholine receptors , 2016, Nature.
[33] C. Altenbach,et al. High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation , 2008, Proceedings of the National Academy of Sciences.
[34] A. IJzerman,et al. Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions. , 2000, Biochemical pharmacology.
[35] R. Lefkowitz,et al. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.
[36] Jonathan R. Tomshine,et al. Conformational biosensors reveal GPCR signalling from endosomes , 2013, Nature.
[37] D. E. Nichols,et al. Crystal Structure of an LSD-Bound Human Serotonin Receptor , 2017, Cell.
[38] A. IJzerman,et al. Structure-kinetics relationships of Capadenoson derivatives as adenosine A1 receptor agonists. , 2015, European journal of medicinal chemistry.
[39] Adriaan P IJzerman,et al. Drug‐Target Residence Time—A Case for G Protein‐Coupled Receptors , 2014, Medicinal research reviews.
[40] Jennifer J Linderman,et al. Modeling of G-protein-coupled Receptor Signaling Pathways* , 2009, Journal of Biological Chemistry.
[41] Arthur Christopoulos,et al. Biased Agonism at G Protein‐Coupled Receptors: The Promise and the Challenges—A Medicinal Chemistry Perspective , 2014, Medicinal research reviews.
[42] Albert C. Pan,et al. Structure and Dynamics of the M3 Muscarinic Acetylcholine Receptor , 2012, Nature.
[43] T. Kenakin,et al. G Protein-Coupled Receptor Allosterism and Complexing , 2002, Pharmacological Reviews.
[44] S. Nuber,et al. β-Arrestin biosensors reveal a rapid, receptor-dependent activation/deactivation cycle , 2016, Nature.
[45] P. Sexton,et al. Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery , 2012, Proceedings of the National Academy of Sciences.
[46] P. Sexton,et al. Ligand-Dependent Modulation of G Protein Conformation Alters Drug Efficacy , 2016, Cell.
[47] Arthur Christopoulos,et al. A simple method for quantifying functional selectivity and agonist bias. , 2012, ACS chemical neuroscience.
[48] O. Nosjean,et al. Prolonged Calcitonin Receptor Signaling by Salmon, but Not Human Calcitonin, Reveals Ligand Bias , 2014, PloS one.
[49] J. Fung,et al. FRET-based measurement of GPCR conformational changes. , 2009, Methods in molecular biology.
[50] Ryan T. Strachan,et al. Divergent Transducer-specific Molecular Efficacies Generate Biased Agonism at a G Protein-coupled Receptor (GPCR)* , 2014, The Journal of Biological Chemistry.
[51] Arthur Christopoulos,et al. Endogenous Allosteric Modulators of G Protein–Coupled Receptors , 2015, The Journal of Pharmacology and Experimental Therapeutics.
[52] J. Violin,et al. Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain. , 2013, Journal of medicinal chemistry.
[53] P. Sexton,et al. Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors , 2004, Journal of Pharmacology and Experimental Therapeutics.
[54] J. Wess,et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor , 2013, Nature.
[55] W. Paton,et al. A theory of drug action based on the rate of drug-receptor combination , 1961, Proceedings of the Royal Society of London. Series B. Biological Sciences.
[56] S. Rasmussen,et al. Allosteric coupling from G protein to the agonist binding pocket in GPCRs , 2016, Nature.
[57] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[58] F. Mitchelson,et al. THE INHIBITORY EFFECT OF GALLAMINE ON MUSCARINIC RECEPTORS , 1976, British journal of pharmacology.
[59] S. Swillens,et al. Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity , 2005, The EMBO journal.
[60] J. Fergus,et al. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. , 1990, Molecular pharmacology.
[61] S. Rasmussen,et al. Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.
[62] J. Changeux,et al. International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands , 2014, Pharmacological Reviews.
[63] Hualiang Jiang,et al. Structural Basis for Molecular Recognition at Serotonin Receptors , 2013, Science.
[64] Eric Trinquet,et al. Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy , 2012, Proceedings of the National Academy of Sciences.
[65] A. Christopoulos,et al. A structure-activity analysis of biased agonism at the dopamine D2 receptor. , 2013, Journal of medicinal chemistry.
[66] Weston B. Struwe,et al. The role of interfacial lipids in stabilizing membrane protein oligomers , 2017, Nature.
[67] T. Kenakin,et al. Analytical pharmacology: the impact of numbers on pharmacology. , 2011, Trends in pharmacological sciences.
[68] J. Vilardaga. ENDOSOMAL GENERATION OF cAMP in GPCR SIGNALING , 2014, Nature chemical biology.
[69] P. Sexton,et al. Allosteric modulation of G protein-coupled receptors: A pharmacological perspective , 2011, Neuropharmacology.
[70] M. Dowling,et al. Exploring the Mechanism of Agonist Efficacy: A Relationship between Efficacy and Agonist Dissociation Rate at the Muscarinic M3 Receptor , 2009, Molecular Pharmacology.
[71] Y. Peterson,et al. The conformational signature of arrestin3 predicts its trafficking and signaling functions , 2016, Nature.
[72] Kunhong Xiao,et al. Multiple ligand-specific conformations of the β2-adrenergic receptor. , 2011, Nature chemical biology.
[73] P. Sexton,et al. A Monod-Wyman-Changeux Mechanism Can Explain G Protein-coupled Receptor (GPCR) Allosteric Modulation* , 2011, The Journal of Biological Chemistry.
[74] I. Gaidarov,et al. Kinetics of 5-HT2B Receptor Signaling: Profound Agonist-Dependent Effects on Signaling Onset and Duration , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[75] P. Sexton,et al. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. , 2007, Trends in pharmacological sciences.
[76] Tamara L. Kinzer-Ursem,et al. Both Ligand- and Cell-Specific Parameters Control Ligand Agonism in a Kinetic Model of G Protein–Coupled Receptor Signaling , 2007, PLoS Comput. Biol..
[77] Albert C. Pan,et al. Pathway and mechanism of drug binding to G-protein-coupled receptors , 2011, Proceedings of the National Academy of Sciences.
[78] A. Kruse,et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist , 2011, Nature.
[79] R. Huber,et al. Structure–kinetic relationship study of CDK8/CycC specific compounds , 2013, Proceedings of the National Academy of Sciences.
[80] Arthur Christopoulos,et al. Advances in G Protein-Coupled Receptor Allostery: From Function to Structure , 2014, Molecular Pharmacology.
[81] G. Cottrell,et al. Endosomes: A legitimate platform for the signaling train , 2009, Proceedings of the National Academy of Sciences.
[82] R. Stevens,et al. Structural Features for Functional Selectivity at Serotonin Receptors , 2013, Science.
[83] Kurt Wüthrich,et al. Biased Signaling Pathways in β2-Adrenergic Receptor Characterized by 19F-NMR , 2012, Science.
[84] F. Ehlert,et al. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. , 1988, Molecular pharmacology.
[85] F. Ehlert. Analysis of Allosterism in Functional Assays , 2005, Journal of Pharmacology and Experimental Therapeutics.
[86] K. Jacobson,et al. Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor , 2016, Molecular Pharmacology.
[87] Arthur Christopoulos,et al. The role of kinetic context in apparent biased agonism at GPCRs , 2016, Nature Communications.
[88] S. Charlton,et al. Long Receptor Residence Time of C26 Contributes to Super Agonist Activity at the Human β2 Adrenoceptor , 2016, Molecular Pharmacology.
[89] R. Copeland. The drug–target residence time model: a 10-year retrospective , 2015, Nature Reviews Drug Discovery.
[90] P. Sexton,et al. Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties , 2010, Neuropsychopharmacology.
[91] L. Mahan,et al. Correction to “The Kinetics of Competitive Radioligand Binding Predicted by the Law of Mass Action” , 2014, Molecular Pharmacology.
[92] J. Violin,et al. Biased ligands at G-protein-coupled receptors: promise and progress. , 2014, Trends in pharmacological sciences.
[93] D. Hall,et al. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. , 2000, Molecular pharmacology.
[94] S. Lazareno,et al. Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. , 2002, Molecular pharmacology.
[95] Robert J. Lefkowitz,et al. Transduction of Receptor Signals by ß-Arrestins , 2005, Science.
[96] Aashish Manglik,et al. Propagation of conformational changes during μ-opioid receptor activation , 2015, Nature.
[97] J. Proska,et al. Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. , 1994, Molecular pharmacology.